Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Egan AG, et al. Among authors: rosebraugh c. N Engl J Med. 2014 Feb 27;370(9):794-7. doi: 10.1056/NEJMp1314078. N Engl J Med. 2014. PMID: 24571751 Free article. No abstract available.
The FDA's assessment of two drugs for chronic weight management.
Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. Colman E, et al. Among authors: rosebraugh c. N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. Epub 2012 Oct 10. N Engl J Med. 2012. PMID: 23050510 Free article. No abstract available.
The risks and benefits of indacaterol--the FDA's review.
Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. Chowdhury BA, et al. Among authors: rosebraugh cj. N Engl J Med. 2011 Dec 15;365(24):2247-9. doi: 10.1056/NEJMp1109621. N Engl J Med. 2011. PMID: 22168640 Free article. No abstract available.
Response.
Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Durmowicz AG, et al. Among authors: rosebraugh cj. Chest. 2013 Oct;144(4):1418-1419. doi: 10.1378/chest.13-1517. Chest. 2013. PMID: 24081359 No abstract available.
27 results